Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.66 |
| ▸ | RELA | Q04206 | 3/20 | 0.66 |
| ▸ | KDR | P35968 | 11/20 | 0.65 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179920 | 0.80 | KDR (1.00) | KDRLCK | |
| SCHEMBL6180047 | 0.80 | KDR (0.77) | KDRLCK | |
| SCHEMBL13524918 | 0.80 | CHEK1 (0.59) | KDR | |
| SCHEMBL7490947 | 0.78 | KDR (0.79) | KDR | |
| SCHEMBL3604852 | 0.78 | NQO2 (0.55) | NPC1MAPTRAB9ASMN1; SMN2KDR | |
| SCHEMBL13701563 | 0.76 | KDR (0.60) | KDRALDH1A1LCKLMNA | |
| SCHEMBL6179560 | 0.76 | KDR (0.78) | NPC1RAB9AKDRMEN1KMT2A | |
| SCHEMBL6182812 | 0.75 | KDR (0.73) | KDR | |
| SCHEMBL2648173 | 0.75 | CNR1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL5840422 | 0.75 | KDR (0.72) | SMN1; SMN2KDRNQO2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218376-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NPC1 3497/4885MAPT 1182/4885RAB9A 2382/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NPC1 3497/4885MAPT 1182/4885RAB9A 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.